AGT
Angiotensinogen
Also known as: ANGT_HUMAN, SERPINA8
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P01019
- Gene
- AGT
- Ensembl
- ENSG00000135744
- Chromosome
- 1
- Canonical length
- 476 aa
- Protein class
- Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
The protein encoded by this gene, pre-angiotensinogen or angiotensinogen precursor, is expressed in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. The resulting product, angiotensin I, is then cleaved by angiotensin converting enzyme (ACE) to generate the physiologically active enzyme angiotensin II. The protein is involved in maintaining blood pressure, body fluid and electrolyte homeostasis, and in the pathogenesis of essential hypertension and preeclampsia. Mutations in this gene are associated with susceptibility to essential hypertension, and can cause renal tubular dysgenesis, a severe disorder of renal tubular development. Defects in this gene have also been associated with non-familial structural atrial fibrillation, and inflammatory bowel disease. [provided by RefSeq, Nov 2019]
Canonical amino-acid sequenceUniProt
476 residues, UniProt reviewed canonical sequence.
>P01019|AGT
1 MAPAGVSLRA TILCLLAWAG LAAGDRVYIH PFHLVIHNES TCEQLAKANA GKPKDPTFIP
61 APIQAKTSPV DEKALQDQLV LVAAKLDTED KLRAAMVGML ANFLGFRIYG MHSELWGVVH
121 GATVLSPTAV FGTLASLYLG ALDHTADRLQ AILGVPWKDK NCTSRLDAHK VLSALQAVQG
181 LLVAQGRADS QAQLLLSTVV GVFTAPGLHL KQPFVQGLAL YTPVVLPRSL DFTELDVAAE
241 KIDRFMQAVT GWKTGCSLMG ASVDSTLAFN TYVHFQGKMK GFSLLAEPQE FWVDNSTSVS
301 VPMLSGMGTF QHWSDIQDNF SVTQVPFTES ACLLLIQPHY ASDLDKVEGL TFQQNSLNWM
361 KKLSPRTIHL TMPQLVLQGS YDLQDLLAQA ELPAILHTEL NLQKLSNDRI RVGEVLNSIF
421 FELEADEREP TESTQQLNKP EVLEVTLNRP FLFAVYDQSA TALHFLGRVA NPLSTALocalizationUniProt · AlphaFold · HPA
Whether an antibody against AGT can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.26
- Highest tissue expression
- 1,555 nTPM
Expression across tissuesHPA
Tissue
- liver: 1,555 nTPM
- basal ganglia: 269 nTPM
- amygdala: 241 nTPM
- midbrain: 207 nTPM
- cerebral cortex: 171 nTPM
- hippocampal formation: 161 nTPM
Single-cell type
- hepatocytes: 2,176 nCPM
- cholangiocytes: 1,050 nCPM
- ependymal cells: 249 nCPM
- astrocytes: 212 nCPM
- epididymal efferent duct absorptive cells: 174 nCPM
- pericytes: 78 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- medulla oblongata: 515 nTPM
- spinal cord: 490 nTPM
- white matter: 435 nTPM
- midbrain: 433 nTPM
- thalamus: 348 nTPM
- cerebellum: 327 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about AGT.
Disease | AllUniProt
Conditions AGT is implicated in, by any mechanism.
- Essential hypertension (EHT) MIM:145500
- Renal tubular dysgenesis (RTD) MIM:267430
Disease | GeneticClinVar
17 pathogenic / likely-pathogenic of 266 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Renal tubular dysgenesis of genetic origin
- Renal tubular dysgenesis
- Essential hypertension, genetic
- Anhydramnios
- Large fontanelles
Disease | AutoantibodyPubMed
Conditions in which antibodies against AGT are reported. Each links to that disease's full target list.
Showing 4 of 5 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for AGT from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
88 publications
- The role of inflammation in the pathology of preeclampsia.
2016 · Clin Sci (Lond) · RCR 20.3 · 435 citations - Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
2005 · N Engl J Med · RCR 16.5 · 689 citations - Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1.
2009 · Hypertension · RCR 5.4 · 167 citations - Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats.
2008 · Hypertension · RCR 4.5 · 151 citations - The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy.
2010 · Am J Hypertens · RCR 3.7 · 116 citations
Show 20 more of 88 total
- Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes.
2011 · Hypertension · RCR 3.5 · 109 citations - Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension.
2000 · J Hypertens · RCR 3.4 · 150 citations - Antibodies against Angiotensin II Type 1 and Endothelin 1 Type A Receptors in Cardiovascular Pathologies.
2022 · Int J Mol Sci · RCR 3.2 · 33 citations - Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy.
2015 · Expert Opin Ther Targets · RCR 2.8 · 62 citations - Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy.
2013 · Hypertension · RCR 2.8 · 77 citations - Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study.
2009 · Hypertension · RCR 2.7 · 83 citations - Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation.
2004 · Circulation · RCR 2.7 · 110 citations - Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis.
2016 · Autoimmun Rev · RCR 2.7 · 65 citations - Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity.
2022 · Sci Adv · RCR 2.6 · 35 citations - Antibodies against Angiotensin II Type 1 and Endothelin A Receptors: Relevance and pathogenicity.
2019 · Hum Immunol · RCR 2.6 · 54 citations - Autoimmunity in Syndromes of Orthostatic Intolerance: An Updated Review.
2024 · J Pers Med · RCR 2.4 · 8 citations - Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats.
2012 · Am J Physiol Regul Integr Comp Physiol · RCR 2.3 · 63 citations - Hypertension in response to AT1-AA: role of reactive oxygen species in pregnancy-induced hypertension.
2011 · Am J Hypertens · RCR 2.3 · 65 citations - Absence of Functional Autoantibodies Targeting Angiotensin II Receptor Type 1 and Endothelin-1 Type A Receptor in Circulation and Purified IgG From Patients With Systemic Sclerosis.
2025 · Arthritis Rheumatol · RCR 2.3 · 6 citations - Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia.
2011 · Curr Opin Pharmacol · RCR 2.3 · 67 citations - Vascular endothelial mitochondrial oxidative stress in response to preeclampsia: a role for angiotension II type 1 autoantibodies.
2021 · Am J Obstet Gynecol MFM · RCR 2.2 · 26 citations - Characterization of Mitochondrial Bioenergetics in Preeclampsia.
2021 · J Clin Med · RCR 1.9 · 21 citations - Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion.
2005 · Am J Hypertens · RCR 1.8 · 63 citations - Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia.
2006 · J Soc Gynecol Investig · RCR 1.8 · 61 citations - Placental CD4+ T cells from preeclamptic patients cause autoantibodies to the angiotensin II type I receptor and hypertension in a pregnant rat model of preeclampsia.
2022 · Explor Med · RCR 1.8 · 17 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.45
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.2
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- angiotensin-activated signaling pathway
- blood vessel remodeling
- cell-cell signaling
- G protein-coupled receptor signaling pathway
- G protein-coupled receptor signaling pathway coupled to cGMP nucleotide second messenger
- kidney development
- low-density lipoprotein particle remodeling
- maintenance of blood vessel diameter homeostasis by renin-angiotensin
- negative regulation of MAP kinase activity
- negative regulation of neurotrophin TRK receptor signaling pathway
- nitric oxide-cGMP-mediated signaling
- phospholipase C-activating G protein-coupled receptor signaling pathway
- positive regulation of branching involved in ureteric bud morphogenesis
- positive regulation of cardiac muscle hypertrophy
- positive regulation of cholesterol metabolic process
- positive regulation of cytokine production
- positive regulation of DNA-templated transcription
- positive regulation of endothelial cell migration
- positive regulation of epidermal growth factor receptor signaling pathway
- positive regulation of epithelial to mesenchymal transition
- positive regulation of extracellular matrix assembly
- positive regulation of extrinsic apoptotic signaling pathway
- positive regulation of fibroblast proliferation
- positive regulation of gap junction assembly
- positive regulation of inflammatory response
- positive regulation of macrophage derived foam cell differentiation
- positive regulation of miRNA transcription
- positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- positive regulation of reactive oxygen species metabolic process
- regulation of apoptotic process
- regulation of blood pressure
- regulation of cardiac conduction
- regulation of cell growth
- regulation of cell population proliferation
- regulation of extracellular matrix assembly
- regulation of renal output by angiotensin
- regulation of renal sodium excretion
- regulation of vasoconstriction
- renal system process
- renin-angiotensin regulation of aldosterone production
- response to angiotensin
- response to muscle activity involved in regulation of muscle adaptation
- vasoconstriction
- regulation of blood volume by renin-angiotensin
Molecular functions
- growth factor activity
- hormone activity
- serine-type endopeptidase inhibitor activity
- type 1 angiotensin receptor binding
- type 2 angiotensin receptor binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Serpin family
- Serpin, conserved site
- Serpin domain
- Serpin superfamily
- Serpin superfamily, domain 1
- Serpin superfamily, domain 2
- Serpin (serine protease inhibitor)
- Angiotensinogen
- Angiotensinogen, serpin domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of AGT in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AGT as an antibody target. Whether an autoantibody or antibody against AGT could matter depends on whether native AGT is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AGT is annotated as secreted, so native AGT circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label AGT as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...